Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a small-cap biotech filing can feel like decoding a lab notebook—especially when Tharimmune’s disclosures span pruritus trial endpoints, antibody constructs and complex licensing terms. If you have ever asked, "How do I navigate a Tharimmune annual report 10-K simplified?" or hunted for Tharimmune insider trading Form 4 transactions, you know the challenge.
Stock Titan solves it. Our AI instantly breaks down every document—so understanding Tharimmune SEC documents with AI means plain-English summaries, key financial tables and alerts the moment a Tharimmune Form 4 insider transactions real-time filing hits EDGAR. Need the latest Tharimmune quarterly earnings report 10-Q filing? We tag R&D spend, cash runway and pipeline updates, then link them to historical trends for quick Tharimmune earnings report filing analysis. Material deal signed or FDA feedback released? The platform flags it inside the next 8-K, giving you Tharimmune 8-K material events explained before the market digests the news.
Here’s what investors regularly track:
- Phase-progress timelines, dosing cohorts and safety data tucked into 10-Q footnotes
- Licensing economics and dilution risk revealed in S-3 and S-1 shelves
- Tharimmune executive stock transactions Form 4 that signal insider confidence
- Board pay details inside the Tharimmune proxy statement executive compensation
Stop wading through 200-page PDFs. Stock Titan delivers AI-powered summaries, expert context and real-time updates on every Tharimmune filing—so you can focus on whether TH104’s buccal film or those multi-specific antibodies are the next breakthrough.
Tharimmune, Inc. (Nasdaq: THAR) filed a Form 8-K disclosing that Board member Kelly Anderson resigned, effective June 22, 2025, citing personal reasons. The filing, signed by CEO Sireesh Appajosyula on June 24, 2025, contains no indication of disagreement with management or issues related to the company’s operations, policies, or practices. No replacement director or related compensatory arrangements were announced. Aside from this governance change, the 8-K includes no financial data, strategic updates, or other material transactions.
Gravitas Capital LP, a significant insider at Tharimmune (THAR), has reported a substantial purchase of company shares. On June 20, 2025, the entity acquired 337,838 shares of Common Stock at a price of $1.48 per share, representing a total investment of approximately $500,000.
Following this transaction, Gravitas Capital LP now owns 732,424 shares directly. The reporting person holds multiple positions within the company, serving as:
- Executive Chairman
- Director
- 10% Owner
This insider purchase by a high-ranking executive and major shareholder could signal confidence in the company's future prospects. The transaction was reported within the required filing deadline, with the Form 4 being signed by Vincent LoPriore on June 23, 2025.
Form 4 filing reveals that Sanam Parikh, Director of Tharimmune (THAR), executed a direct purchase of company shares on June 20, 2025. The insider transaction details:
- Acquired 1,000 shares of Common Stock at $1.45 per share
- Total transaction value: $1,450
- Following the purchase, Parikh now holds 1,770 shares directly
This insider buying activity by a board member could signal confidence in the company's future prospects. The transaction was reported within the required filing window, with the Form 4 being signed on June 23, 2025. No derivative securities were involved in this transaction.
FAQ
What is the current stock price of Tharimmune (THAR)?
What is the market cap of Tharimmune (THAR)?
